{"id":"W2759791460","doi":"10.1160/th17-03-0171","title":"Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial","year":2017,"lang":"en","type":"article","venue":"Thrombosis and Haemostasis","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; McMaster University","funders":"National Heart, Lung, and Blood Institute; LEO Pharma; Cleveland Clinic; Sanofi; Janssen Pharmaceuticals; AstraZeneca; Daiichi-Sankyo; Amgen; Pfizer; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Medicine; Rivaroxaban; Pulmonary embolism; Deep vein; Randomized controlled trial; Ambulatory; Placebo; Thrombosis; Surgery; Internal medicine; Randomization; Asymptomatic; Cancer; Warfarin; Atrial fibrillation","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01538775,0.00213147,0.004405897,0.0004864223,0.001017575,0.00257653,0.001235965,0.003803659,0.005097784],"category_scores_gemma":[0.01083973,0.0008096807,0.002491105,0.0009087498,0.001857484,0.001225311,0.000953852,0.003699496,0.001929229],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007560066,"about_ca_system_score_gemma":0.002697846,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003798121,"about_ca_topic_score_gemma":0.0006313052,"domain_scores_codex":[0.9921217,0.005553922,0.0006076994,0.0006709276,0.0006640844,0.0003816623],"domain_scores_gemma":[0.9972012,0.0008831877,0.000484051,0.0002623992,0.0003588748,0.0008102375],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.8297305,0.008551145,0.007037989,0.01222168,0.003985557,0.0005493034,0.000392678,0.002694828,0.004943474,0.01366542,0.01979855,0.09642892],"study_design_scores_gemma":[0.9198804,0.03310324,0.004134553,0.001414951,0.002497145,0.0002370524,0.00005688667,0.001967254,0.0007222933,0.006007091,0.02990174,0.00007723441],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.2982895,0.1366273,0.02338287,0.03858345,0.01921147,0.4181665,0.009303734,0.0007726896,0.05566242],"genre_scores_gemma":[0.4731295,0.03127944,0.0411744,0.0226023,0.01331476,0.404149,0.003841296,0.0001441063,0.01036536],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.01538775,"threshold_uncertainty_score":0.08137923,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05345014484529672,"score_gpt":0.3101135375704843,"score_spread":0.2566633927251876,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}